Beam Therapeutics reports on the progress of the in vitro and in vivo pipelines for basic editing therapy and outlines key expected milestones in 2022 – QNT Press Release


The first subject is expected to participate in the BEAM-101 Phase 1/2 clinical trial for sickle cell disease in the second half of 2022

BEAM-301 was named as the fourth drug candidate for the treatment of type Ia glycogen storage disease

Two other development candidates are expected to be nominated in 2022

The company will show pipeline and business updates at the age of 40day The annual JPMorgan Chase Healthcare Conference on January 10, 2022 at 2:15 p.m. Eastern Time

Cambridge, Massachusetts, January 9, 2022 (Global News Agency) – Beam Therapeutics Inc. (Nasdaq:beam), a biotechnology company that develops precision gene drugs through base editing, today outlined its projected milestones in 2022 In vitro Programs and programs aimed at editing hematopoietic stem cells (HSC) and T cells in vivo Program for editing hepatocytes using lipid nanoparticles (LNP).The update includes that the company has selected the fourth development candidate and the first in vivo The base editing candidate BEAM-301 aims to correct the R83C mutation and potentially treat patients with glycogen storage disease Ia (GSDIa).

“We have made significant progress in the base editing product portfolio in 2021, and finally the US Food and Drug Administration approved the first research new drug application for the base editing therapeutic BEAM-101. We have also further expanded our platform , Especially LNP delivery Beam CEO John Evans said: “We believe that 2022 will be our most important year. We are preparing to start BEACON-101 clinical trials and BEAM-101 treatment of sickle cell disease, and complete Our transition to a clinical stage company. We believe that we are in a favorable position today. With four candidate developers, a rich pipeline of early projects, and an industry-leading editing and delivery technology platform, we can launch a new type of precision gene medicine. All this is impossible without the commitment of our outstanding and fearless innovation team. We look forward to the coming year and continue our work to provide as many patients as possible with life-changing drugs. “

Past life HSC courses

  • BEAM-101 is an autologous HSC research therapy for patients that combines base editing and aims to mimic the single nucleotide polymorphisms seen in individuals with inherited fetal hemoglobin persistence. BEAM-101 aims to potentially…

The full story can be found on Benzinga.com



Source link

Recommended For You

About the Author: News Center